Quantum BioPharma Moves to Lead Class Action Alleging Bank Manipulation of Its Shares

Quantum Biopharma ( (TSE:QNTM) ) has shared an update.

On December 22, 2025, Quantum BioPharma announced that a shareholder, represented by U.S. law firm Grant & Eisenhofer, filed a class action lawsuit in which investors allege that they were victims of stock manipulation by Canadian banks CIBC and RBC between January 6, 2021, and October 15, 2025, claiming significant harm to shareholders who sold Quantum BioPharma (formerly FSD Pharma) securities during that period. The company said it plans to seek appointment as a lead plaintiff in the action to help protect shareholder interests and also disclosed that it has renewed the services of LWM for one month starting December 22, 2025, signaling an active stance in addressing alleged market abuses that may have affected its share price and potentially reshaped its relationship with major financial institutions and investors.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative therapies for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various stages of development. Through its wholly owned subsidiary Lucid Psycheceuticals, the company is advancing Lucid-MS, a patented new chemical entity that has shown an ability in preclinical models to prevent and reverse myelin degradation, the core mechanism of multiple sclerosis. Quantum BioPharma also invented the alcohol-related product unbuzzd, retaining an equity stake and royalty rights in Unbuzzd Wellness Inc., and maintains a portfolio of strategic, property-backed investments via its subsidiary FSD Strategic Investments Inc.

YTD Price Performance: 110.60%

Average Trading Volume: 4,739

Technical Sentiment Signal: Sell

Current Market Cap: C$47.03M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.